Inogen adds COO to executive team

BEVERLY, Mass. – Inogen has appointed Andy Reding to the newly created role of COO. Reding will be responsible for driving revenue and operational performance, aligning cross-functional priorities, and helping ensure Inogen’s strategy is translated into efficient and measurable outcomes. “As we continue to diversify Inogen’s business through new product launches and geographic expansion, we are streamlining our leadership structure to enhance execution and accelerate delivery of our strategic priorities,” said Kevin Smith, CEO of Inogen. “Andy’s deep experience building high-performing teams and scaling complex medical technology businesses will be invaluable as we continue to drive top-line growth, advance profitability and expand the innovation pipeline.” Reding joins Inogen with more than 30 years of leadership experience across medical technology, commercial operations, product development and health care reimbursement. Most recently, he served as chief commercial officer of Viant Medical, where he led teams supporting complex medical-device design and manufacturing programs. He also previously served as vice president and general manager of Hillrom Respiratory Health. During his tenure, his team expanded the sales force, developed new products, and navigated FDA and CMS requirements to bring products to market. Reding will receive an inducement equity award of restricted stock units (“RSUs”) covering an aggregate of 130,000 shares of Inogen’s common stock. Subject to his continued service with Inogen, one-third of the RSUs will vest annually over three years.

Related: Inogen rides B2B tailwind, as POC adoption reshapes channel mix